Correlation of Automated Chemiluminescent Method with Enzyme-Linked Immunosorbent Assay (ELISA) Antibody Titers in Convalescent COVID-19 Plasma Samples: Development of Rapid, Cost-Effective Semi-Quantitative Diagnostic Methods

References

• World Health Organization. Coronavirus disease (COVID-19) Weekly Epidemiological Update and Weekly Operational Update. Available from: https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports. Accessed 10 November 2020.
   Google Scholar
• Duan K, Liu B, Li C, et al. Effectiveness of convalescent plasma therapy in severe COVID-19 patients. PNAS. 2020;117(17):9490–9496. doi:10.1073/pnas.2004168117
   PubMed Web of Science ®Google Scholar
• Shen C, Wang Z, Zhao F, et al. Treatment of 5 critically Ill patients with COVID-19 with convalescent plasma. JAMA. 2020;323(16):1582–1589. doi:10.1001/jama.2020.4783
   PubMed Web of Science ®Google Scholar
• Chen L, Xiong J, Bao L, Shi Y. Convalescent plasma as a potential therapy for COVID-19. Lancet Infect Dis. 2020;20(4):398–400. doi:10.1016/S1473-3099(20)30141-9
   PubMed Web of Science ®Google Scholar
• Liu STH, Lin HM, Baine I, et al. Convalescent plasma treatment of severe COVID-19: a propensity score–matched control study. Nat Med. 2020;26:1708–1713. doi:10.1038/s41591-020-1088-9
   PubMed Web of Science ®Google Scholar
• Joyner MJ, Senefeld JW, Klasses SA, et al. Effect of convalescent plasma on mortality among hospitalized patients with COVID-19: initial three-month experience. MedRxiv. doi:10.1101/2020.08.12.20169359
   Google Scholar
• Wu F, Liu M, Wang A, et al. Evaluating the association of clinical characteristics with neutralizing antibody levels in patients who have recovered from mild COVID-19 in Shanghai, China. JAMA Intern Med. 2020;180(10):1356. doi:10.1001/jamainternmed.2020.4616
   PubMed Web of Science ®Google Scholar
• Choe P, Kang C, Suh H, et al. Antibody responses to SARS-CoV-2 at 8 weeks postinfection in asymptomatic patients. Emerg Infect Dis. 2020;26(10):2484–2487. doi:10.3201/eid2610.202211
   Web of Science ®Google Scholar
• Ibarrondo FJ, Fulcher JA, Goodman-Meza D, et al. Rapid decay of anti–SARS-CoV-2 antibodies in persons with mild COVID-19. N Engl J Med. 2020;383(11):1085–1087. doi:10.1056/NEJMc2025179
   PubMed Web of Science ®Google Scholar
• FDA. Recommendations for Investigational COVID-19 Convalescent Plasma. Available from: https://www.fda.gov/vaccines-blood-biologics/investigational-new-drug-ind-or-device-exemption-ide-process-cber/recommendations-investigational-COVID-19-convalescent-plasma. Accessed 16 November 2020.
   Google Scholar
• Nie J, Li Q, Wu J, et al. Establishment and validation of a pseudovirus neutralization assay for SARS-CoV-2. Emerg. Microbes Infect. 2020;9:680–686. doi:10.1080/22221751.2020.1743767
   PubMed Web of Science ®Google Scholar
• Tang YW, Schmitz JE, Persing DH, Stratton CW. The laboratory diagnosis of COVID-19 infection: current issues and challenges. J Clin Microbiol. 2020;58:e00512–20. doi:10.1128/JCM.00512-20
   PubMed Web of Science ®Google Scholar
• Tan CW, Chia WN, Qin X, et al. A SARS-CoV-2 surrogate virus neutralization test based on antibody-mediated blockage of ACE2–spike protein–protein interaction. Nat Biotechnol. 2020;38(9):1073–1078. doi:10.1038/s41587-020-0631-z
   PubMed Web of Science ®Google Scholar
• Salazar E, Kuchipudi SV, Christensen PA, et al.Relationship between Anti-Spike Protein Antibody Titers and SARS-CoV-2 In Vitro Virus Neutralization in Convalescent Plasma. Preprint. bioRxiv. 2020;. doi:10.1101/2020.06.08.138990.
   Google Scholar
• Campbell AK, Patel A. A homogeneous immunoassay for cyclic nucleotides based on chemiluminescence energy transfer. Biochem J. 1983;216(1):185–194. doi:10.1042/bj2160185
   Web of Science ®Google Scholar
• Vo-Dinh T. Chemiluminescence. Encyclopedia of Applied Physics. 2003. doi:10.1002/3527600434.eap063
   Google Scholar
• Wang YFW, Kobayashi M. Antibody Detection: Principles and Applications/Advanced Techniques in Diagnostic Microbiology. Springer US; 2013:53–73.
   Google Scholar
• Cinquanta L, Fontana DE, Bizzaro N. Chemiluminescent immunoassay technology: what does it change in autoantibody detection? Auto Immun Highlights. 2017;8:9. doi:10.1007/s13317-017-0097-2
   PubMed Web of Science ®Google Scholar
• Weidner L, Gansdorfer S, Unterweger S, et al. Quantification of SARS-CoV-2 antibodies with eight commercially available immunoassays. J of Clin Vir. 2020;129:104540. doi:10.1016/j.jcv.2020.104540
   PubMed Web of Science ®Google Scholar
• Kohmer N, Westhaus S, Rühl C, Ciesek S, Rabenau HF. Clinical performance of different SARS-CoV-2 IgG antibody tests. J. Med. Virol. 2020;1–5. doi:10.1002/jmv.26145
   Web of Science ®Google Scholar
• Perera RAPM, Mok CKP, Tsang OTY, et al. Serological assays for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), March 2020. Eurosurveillance. 2020;25(16). doi:10.2807/1560-7917.ES.2020.25.16.2000421
   Web of Science ®Google Scholar
• Madiyal M, Sagar S, Vishwanath S, Banerjee B, Eshwara VK, Chawla K. Comparing Assay Performance of ELISA and Chemiluminescence Immunoassay in Detecting Antibodies to Hepatitis B Surface Antigen. J Clin Diagn Res. 2016;10:DC22–DC25. doi:10.7860/JCDR/2016/24108.8921
   Google Scholar
• de Ory F, Minguito T, Balfagón P, Sanz JC. Comparison of chemiluminescent immunoassay and ELISA for measles IgG and IgM. APMIS. 2015;123(8):648–651. doi:10.1111/apm.12413
   Web of Science ®Google Scholar
• Chen D, Zhang Y, Xu Y, et al. Comparison of chemiluminescence immunoassay, enzyme-linked immunosorbent assay and passive agglutination for diagnosis of Mycoplasma pneumoniae infection. Ther Clin Risk Manag. 2018;14:1091–1097. doi:10.2147/TCRM.S159227
   PubMed Web of Science ®Google Scholar
• Chang L, Zhao J, Guo F, et al. Comparative evaluation and measure of accuracy of ELISAs, CLIAs, and ECLIAs for the detection of HIV infection among blood donors in China. Can J Infect Dis Med Microbiol. 2020;2020:2164685. doi:10.1155/2020/2164685
   Web of Science ®Google Scholar
• Klein S, Pekosz A, Park H-S, et al. Sex, age, and hospitalization drive antibody responses in a COVID-19 convalescent plasma donor population. J Clin Invest. 2020;130(11):6141–6150. doi:10.1172/JCI142004
   PubMed Web of Science ®Google Scholar
• Madariaga MLL, Guthmiller JJ, Schrantz S, et al. Clinical predictors of donor antibody titre and correlation with recipient antibody response in a COVID-19 convalescent plasma clinical trial. J Intern Med. 2020. doi:10.1111/joim.13185
   Web of Science ®Google Scholar
• Robbiani DF, Gaebler C, Muecksch F, et al. Convergent antibody responses to SARS-CoV-2 in convalescent individuals. Nature. 2020;584(7821):437–442. doi:10.1038/s41586-020-2456-9
   PubMed Web of Science ®Google Scholar
• Luchsinger LL, Ransegnola BP, Jin DK, et al. Serological assays estimate highly variable SARS-CoV_2 neutralizing antibody activity in recovered COVID-19 patients. J. Clin. Microbiol. 2020. doi:10.1128/JCM.02005-20
   Web of Science ®Google Scholar
• https://www.fda.gov/media/141477/download. Accessed March 2, 2021.
   Google Scholar